Medical scientific publisher Informa Healthcare, UK, a division of Informa plc, has announced that its Pharmaceutical Science division has posted the highlights of its latest Journal Impact Factor results, with impressive results across the division's range of titles. Critical Reviews in Toxicology, currently ranked second out of 77 titles in the competitive Toxicology category, registered an IF increase of 39 percent to 5.145; Critical Reviews in Clinical Laboratory Science is ranked first in the Medical Lab Technology category; and Annals of Medicine, now ranked tenth in its sector, is making gains with an increase of more than 20 percent over the year to 5.779.
Impact Factors are a method of measuring the influence which a journal has on the scientific community. They are calculated by Thomson Reuters and are designed to indicate how many times the published articles of a journal are cited during the course of a year. These are seen to provide an insight to how much 'impact' the journal is making on its audiences.
Informa's results, across its range of Pharmaceutical Science titles, are thus: International Reviews of Immunology is up 92% to 3.595; Cytotherapy is up 64% to 3.553; Journal of Liposome Research has recorded a 95% increase to 2.021; Chronobiology International is up 47% to 3.707; and Expert Opinion on Therapeutic Targets is up 25% to 3.333. Overall, Impact Factors across the division's range of 41 titles are up 7.3% year-on-year. Another new Informa title to enter the market with a remarkable impact was the International Journal of Pediatric Obesity, which registered an IF of 2.00 in its first year in the market.
